{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:16:04Z","timestamp":1776903364637,"version":"3.51.2"},"reference-count":120,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T00:00:00Z","timestamp":1560211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Aggressive T\u2010cell lymphomas continue to have a poor prognosis. There are over 27 different subtypes of peripheral T\u2010cell lymphoma (PTCL) and we are now beginning to understand the differences between the various subtypes beyond histologic variations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Molecular pathogenesis of various subtypes of PTCL<\/jats:title><jats:p>Gene expression profiling can help in diagnosis and prognostication of various subtypes including PTCL\u2010nos and anaplastic large cell lymphoma. In addition, mutational analysis is now being incorporated in clinical trials of novel agents to evaluate various biomarkers of response to allow better therapeutic choices for patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Targeted therapies<\/jats:title><jats:p>There are many targeted agents currently in various stages of clinical trials for PTCL that take advantage of the differential expression of specific proteins or receptors in PTCL tumors. The most promising is the CD30 directed antibody drug conjugate brentuximab vedotin. This has recently been approved by the Food and Drug Administration for the upfront treatment of CD30 expressing PTCLs in combination with cyclophosphamide, doxorubicin, and prednisone chemotherapy. Other notable targets are CD25, CCR4 tag, PI3kinase inhibitors, and JAK\/STAT inhibitors. Anaplastic lymphoma kinase (ALK) inhibitors are promising for ALK expressing tumors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Immunotherapies<\/jats:title><jats:p>The use of checkpoint inhibitors in the treatment of PTCL is still controversial. The most promising results have been seen in cases of extranodal natural killer cell\/T\u2010cell lymphomas and cutaneous T\u2010cell lymphomas. For all other subtypes, immune checkpoint inhibitors should be used with extreme caution and only in the context of a clinical trial. Allogeneic stem cell transplant continues to be the curative therapy for most aggressive subtypes of PTCL.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ajh.25513","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T14:39:10Z","timestamp":1558622350000},"page":"929-946","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Aggressive T\u2010cell lymphomas: 2019 updates on diagnosis, risk stratification, and management"],"prefix":"10.1002","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4308-629X","authenticated-orcid":false,"given":"Jasmine M.","family":"Zain","sequence":"first","affiliation":[{"name":"Department of Hematology\/Hematopoietic Cell Transplantation City of Hope Medical Center  Duarte California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,6,11]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2009.05.001"},{"key":"e_1_2_9_4_1","unstructured":"National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology for Non\u2010Hodgkin's Lymphomas Version 2.2019. Available at:https:\/\/wwwnccnorg\/professionals\/physician_gls\/defaultaspx#site; 2019. Accessed December 17 2018."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573089"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802455867"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh392"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30416"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12248"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-020117-043821"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-99716-2_2"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.2083"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-310342"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2016.11.009"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-544809"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.5611"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-99716-2_4"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e328186ffbf"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-99716-2_5"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07042.x"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408542"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-531509"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-11"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4164.4164"},{"issue":"1","key":"e_1_2_9_27_1","first-page":"1515","article-title":"A phase 1\/2 study of oral 5\u2010azacitidine and romidepsin in patients with lymphoid malignancies reveals promising activity in heavily pretreated peripheral T\u2010cell lymphoma (PTCL)","volume":"130","author":"Falchi L","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.11.3913"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1064530"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-0945-5"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-571091"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-838524"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-99716-2_6"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000002010"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.3412"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjw065"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.131151"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-755496"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31266-7"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70095-0"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-99716-2_7"},{"issue":"10","key":"e_1_2_9_45_1","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T\u2010cell leukemia\/lymphoma: its close association with skin involvement and unfavorable outcome","volume":"9","author":"Ishida T","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0371"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3564"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6424"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3415"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-662593"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5578"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2697"},{"issue":"22","key":"e_1_2_9_53_1","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1182\/blood.V128.22.4159.4159","article-title":"A prospective, multicenter, randomized study of anti\u2010CCR4 monoclonal antibody Mogamulizumab versus Investigator's choice in the treatment of patients with relapsed\/refractory adult T\u2010cell leukemia\u2010lymphoma: overall response rate, progression\u2010free survival, and overall survival","volume":"128","author":"Phillips A","year":"2016","journal-title":"Blood"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00284-7"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2012.01.014"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1620036114"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-231324"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.09.016"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7025"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.280"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.43"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-087288"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1597"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins5081402"},{"issue":"1","key":"e_1_2_9_65_1","first-page":"1512","article-title":"Outcome of patients with Gamma Delta T cell lymphomas: analysis of 1429 cases registered in the prospective T\u2010cell project","volume":"130","author":"Foss FM","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-99716-2_8"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02885.x"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.5304"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3127-2"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-756841"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01120-4"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1605684"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv596"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114110"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2439_190"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13855"},{"issue":"23","key":"e_1_2_9_77_1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood.V126.23.253.253","article-title":"Safe and effective treatment of patients with peripheral T\u2010cell lymphoma (PTCL) with the novel HDAC inhibitor, Belinostat, in combination with CHOP: results of the bel\u2010CHOP phase 1 trial","volume":"126","author":"Johnston PB","year":"2015","journal-title":"Blood"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00023-X"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.2456"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27733"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-99716-2_13"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31861"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3472"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv237"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-542142"},{"key":"e_1_2_9_87_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2679.2679","article-title":"Second line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed\/ refractory peripehral T\u2010 cell lymphomas: minimal benefit when analyxed by intent to treat","volume":"106","author":"Horwitz S","year":"2005","journal-title":"Blood"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2309-z"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.7285"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3389"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.04.029"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2468-y"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112869"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1366"},{"key":"e_1_2_9_95_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2144"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.084913"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116741"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2007.02195.x"},{"issue":"3","key":"e_1_2_9_99_1","first-page":"506","article-title":"IL\u20102 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases","volume":"126","author":"Strauchen JA","year":"1987","journal-title":"Am J Pathol"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2005.12.017"},{"key":"e_1_2_9_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.11.4063.bloodjournal86114063"},{"issue":"1","key":"e_1_2_9_102_1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/blood-2018-99-116907","article-title":"Phase I study of Yttrium\u201090 labeled ANTI\u2010CD25 (aTac) monoclonal antibody PLUS BEAM for autologous hematopoietic CELL transplantation (AHCT) in patients with mature T\u2010CELL NON\u2010Hodgkin lymphoma, the \"a\u2010TAC\u2010BEAM regimen\"","volume":"132","author":"Zain J","year":"2018","journal-title":"Blood"},{"issue":"1","key":"e_1_2_9_103_1","first-page":"1510","article-title":"Interim results from a phase 1 study of ADCT\u2010301 (Camidanlumab Tesirine) show promising activity of a novel pyrrolobenzodiazepine\u2010based antibody drug conjugate in relapsed\/refractory Hodgkin\/non\u2010Hodgkin lymphoma","volume":"130","author":"Horwitz SM","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6"},{"issue":"1","key":"e_1_2_9_105_1","first-page":"5179","article-title":"Mogamulizumab monotherapy in the treatment of relapsed\/refractory peripheral T\u2010cell lymphoma or cutaneous T\u2010cell lymphoma patients in single\u2010institution experience","volume":"130","author":"Murai K","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_106_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13338"},{"key":"e_1_2_9_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.04.016"},{"key":"e_1_2_9_108_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-802470"},{"key":"e_1_2_9_109_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112757"},{"key":"e_1_2_9_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112123"},{"key":"e_1_2_9_111_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119944"},{"key":"e_1_2_9_112_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2359-2"},{"issue":"1","key":"e_1_2_9_113_1","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood-2018-99-111885","article-title":"Daratumumab monotherapy for patients with relapsed or refractory (R\/R) natural killer\/T\u2010cell lymphoma (NKTCL), nasal type: an open\u2010label, single\u2010arm, multicenter phase 2 study","volume":"132","author":"Kim W\u2010S","year":"2018","journal-title":"Blood"},{"key":"e_1_2_9_114_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29103"},{"key":"e_1_2_9_115_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.8521"},{"key":"e_1_2_9_116_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.821.821"},{"key":"e_1_2_9_117_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.181.181"},{"key":"e_1_2_9_118_1","doi-asserted-by":"publisher","DOI":"10.21037\/aol.2018.03.02"},{"key":"e_1_2_9_119_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1803181"},{"key":"e_1_2_9_120_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807315"},{"key":"e_1_2_9_121_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000468"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.25513","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25513","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.25513","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T17:53:11Z","timestamp":1694281991000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.25513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,11]]},"references-count":120,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1002\/ajh.25513"],"URL":"https:\/\/doi.org\/10.1002\/ajh.25513","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,11]]},"assertion":[{"value":"2019-02-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}